{
    "clinical_study": {
        "@rank": "114546", 
        "brief_summary": {
            "textblock": "To compare the safety and effectiveness of itraconazole oral solution to placebo in the\n      treatment of a pulmonary aspergilloma.\n\n      Aspergilloma is a \"fungal ball\" in the lungs caused by Aspergillus. The infection can spread\n      from the lungs through the blood to other organs. Aspergilloma can be life-threatening;\n      therefore, an effective treatment is needed."
        }, 
        "brief_title": "A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma", 
        "completion_date": "November 2005", 
        "condition": [
            "Aspergillosis", 
            "Lung Diseases, Fungal"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aspergillosis", 
                "Lung Diseases", 
                "Lung Diseases, Fungal"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomly selected to receive itraconazole oral solution by mouth or the\n      inactive placebo (oral cyclodextrin solution) twice daily for 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        You may be eligible for this study if you:\n\n          -  Are 18 years of age or older.\n\n          -  Have been diagnosed with aspergilloma within the last month.\n\n          -  Have (or have a history of) at least one of the following:\n\n               1. positive test for Aspergillus species.\n\n               2. presence of antibodies to Aspergillus.\n\n          -  Are willing to participate in the study for 2 full years.\n\n          -  Are female and not pregnant.\n\n          -  Are not breast-feeding.\n\n          -  Agree to use barrier methods of birth control / contraception during the study and\n             for 30 days after.\n\n        Exclusion Criteria:\n\n        You will not be eligible for this study if you:\n\n          -  Have a history of allergy to triazole or imidazole drugs.\n\n          -  Are unable to take oral medication.\n\n          -  Are not expected to live for more than a month.\n\n          -  Have had a lung biopsy indicating Aspergillus infection.\n\n          -  Have had radiation therapy within the last 6 months.\n\n          -  Require treatment with certain medications.\n\n          -  Received amphotericin, amphotericin lipid formulation, fluconazole, or itraconazole\n             in the two weeks prior to study entry.\n\n          -  Received chemotherapy within the last 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "96", 
        "firstreceived_date": "May 18, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005668", 
            "org_study_id": "DMID MSG 37", 
            "secondary_id": [
                "DMID 96-199", 
                "NIH/09021"
            ]
        }, 
        "intervention": {
            "intervention_name": "Itraconazole oral solution", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "lastchanged_date": "August 26, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "Mary Ellen Bradley"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005668"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2005"
    }, 
    "geocoordinates": {
        "Mary Ellen Bradley": "33.521 -86.802"
    }
}